The Science of Sequencing: Navigating Complexities in HER2+ Metastatic Breast Cancer Care Beyond Second-line Therapy

Community oncologists, neuro-oncologists, and other oncology HCPs who treat patients with HER2+ metastatic breast cancer will be able to summarize and describe the treatment sequence of HER2-targeted therapies and tyrosine kinase inhibitor combination regimens, and interpret recent clinical data, to improve patient outcomes.

Share

Program Content

Events

Activities

Sequencing HER2 Positive  MBC
Sequencing HER2+ Metastatic Breast Cancer Care Beyond Second-line Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 04, 2025

Expires: March 03, 2026

Brain Metastases HER2 Positive  MBC
Navigating Complexities and Brain Metastases When Sequencing HER2+ Metastatic Breast Cancer Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 04, 2025

Expires: March 03, 2026

Activities

Sequencing Tx HER2 MBC
Expert Thoughts on Sequencing Therapy for Patients With HER2+ Metastatic Breast Cancer 
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2025

Expires: January 28, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.